Examination of Topoisomerase I (TOPO1) Expression in Metastatic GI Cancers | Caris Life Sciences
Portal
Order
Home / Research / Publications / Examination of Topoisomerase I (TOPO1) Expression in Metastatic GI Cancers

Publications

Back

Examination of Topoisomerase I (TOPO1) Expression in Metastatic GI Cancers

– Caris Life Sciences

Poster

Background

Irinotecan failed in Stage III colon cancer, but succeeds in Stage IV, to prolong survival. We propose that TOPO1 over-expression is a phenomenon of metastatic disease, and perhaps part of the epithelial-mesenchymal-transition (EMT) associated with metastatic phenotypes.

Download Publication

Discover
More

  • TERT Gene Fusions Characterize a Subset of Metastatic Leydig Cell Tumors

    – Caris Life Sciences

    Manuscript

    Abstract Objective Metastatic Leydig cell tumors (LCT) are rare, difficult-to-treat malignancies without known underlying molecular–genetic events. An index case of metastatic LCT showed an LDLR–TERT gene fusion upon routine… […]

  • Comprehensive molecular profiling of paired patient samples of primary and metastatic (met) pancreatic ductal adenocarcinoma (PDAC)

    – Caris Life Sciences

    Poster

    Introduction: The prevailing thinking about PDAC is that primary and metastatic lesions have similar frequencies of genetic mutations. In addition, metastatic lesions are thought to… […]
Learn More

Ready to Get Started on the Journey?

Name(Required)